MihalekRMBowersBJWehnerJMKralicJEVanDorenMJMorrowALet al
Important Note: These potential benefits are based primarily on animal data and anecdotal use, not clinical trials in women
As more clinical data demonstrates that GLP-1 medications produce sustained weight loss and reduce obesity-related comorbidities, coverage is expanding
As the levels of semaglutide drop, the benefits (such as lower blood sugar and reduced appetite) fade gradually
Nutritional approaches emphasizing whole foods, adequate protein, and limited ultra-processed foods support overall metabolic health, though no specific diet directly lowers cortisol in a clinically meaningful way
Monitoring GPx decrease, as a parameter, also allows a therapeutic control, through antioxidant treatment